874360-10-8

Basic information

• Product Name: tert-butyl [(1S,2R,5S)-5-[3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-2-(2,4,5-trifluorophenyl)cyclohexyl]carbamate
• Synonyms: tert-butyl [(1S,2R,5S)-5-[3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-2-(2,4,5-trifluorophenyl)cyclohexyl]carbamate
• CAS NO: 874360-10-8
• Molecular Weight: 519.49
• Mol File: 874360-10-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: tert-butyl [(1S,2R,5S)-5-[3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-2-(2,4,5-trifluorophenyl)cyclohexyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl [(1S,2R,5S)-5-[3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-2-(2,4,5-trifluorophenyl)cyclohexyl]carbamate(874360-10-8)
• EPA Substance Registry System: tert-butyl [(1S,2R,5S)-5-[3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-2-(2,4,5-trifluorophenyl)cyclohexyl]carbamate(874360-10-8)

Safety Data

• Hazardous Substances Data: 874360-10-8(Hazardous Substances Data)

Upstream product

• 874359-92-9 tert-butyl [(1S,2R)-5-oxo-2-(2,4,5-trifluorophenyl)cyclohexyl]carbamate 
• 486460-21-3 3-trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 762240-92-6 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 874359-98-5 {[3-azido-4-(2,4,5-trifluorophenyl)cyclohex-1-en-1-yl]oxy}(triisopropyl)silane 
• 874359-97-4 triisopropyl {[4-(2,4,5-trifluorophenyl)cyclohex-1-en-1-yl]oxy}silane 
• 874359-96-3 4-(2,4,5-trifluorophenyl)cyclohexan-1-one 
• 874359-95-2 8-(2,4,5-trifluorophenyl)-1,4-dioxaspiro[4.5]decane 
• 874359-94-1 8-(2,4,5-trifluorophenyl)-1,4-dioxaspiro[4.5]dec-7-ene 
• 874359-93-0 8-(2,4,5-trifluorophenyl)-1,4-dioxaspiro[4.5]decan-8-ol 

Relevant articles and documents

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin

Molecular modeling was used to design a rigid analog of sitagliptin 1. The X-ray crystal structure of sitagliptin bound to DPP-4 suggested that the central β-amino butyl amide moiety could be replaced with a cyclohexylamine group. This was confirmed by structural analysis and the resulting analog 2a was synthesized and found to be a potent DPP-4 inhibitor (IC50 = 21 nM) with excellent in vivo activity and pharmacokinetic profile.